Inclusion Criteria:

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization for release of personal health information

               -  NOTE: HIPAA authorization may be included in the informed consent or obtained
                  separately

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days
             prior to being registered for protocol therapy

          -  Females of childbearing potential and males must be willing to use an effective method
             of contraception (hormonal or barrier method of birth control; abstinence) from the
             time consent is signed until 4 weeks after treatment discontinuation

          -  Females of childbearing potential must have a negative pregnancy test within 7 days
             prior to being registered for protocol therapy

               -  NOTE: Subjects are considered not of child bearing potential if they are
                  surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation,
                  or bilateral oophorectomy) or they are postmenopausal

          -  Females must not be breastfeeding

          -  Cohort A - T2, Transitional cell carcinoma (TCC) muscle invasive bladder cancer,
             (patients who are cisplatin ineligible, decline neoadjuvant and/or ineligible for
             neoadjuvant chemotherapy); must have histological proof of T2, muscle-invasive
             transitional cell carcinoma of the bladder with no evidence of metastatic; patient
             with any degree of fixation of the pelvic sidewall are not eligible

          -  Cohort B - Prostate cancer (Gleason 7 or less); must have histological proof of
             Gleason =< 7 with no evidence of metastatic disease (patient with any degree of
             extra-prostatic capsule extension are not eligible

          -  Cohort C - Renal cell carcinoma (> pT1b); must have radiologic suspicion or
             histological proof of clear cell renal cell carcinoma >= 4 cm with no evidence of
             metastatic disease; patient with any degree of tumor extension into the renal vein are
             not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS)
             imaging and agree to undergo this additional imaging technique

          -  Patients must be willing to undergo a biopsy of the cancerous tissue if one was not
             taken within the previous year, prior to drug initiation if tumor block is not
             available; biopsy must be done within 14 days of first planned drug dose

          -  Patients must be willing to undergo a radiologic scan (computed tomography [CT] or
             magnetic resonance imaging [MRI], depending on organ involved) after last drug dose
             and prior to minimally-invasive surgery

          -  Eligible for:

               -  Cohort A: Robot-assisted radical cystectomy (RARC) as per the attending urologist

               -  Cohort B: Robot-assisted radical Nephrectomy (RARN)/robot-assisted partial
                  nephrectomy (RAPN) as per the attending urologist

               -  Cohort C: RAPN as per the attending urologist

          -  No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or other cancers for which the patient has
             been disease-free for at least 5 years

          -  No treatment with any investigational agent within 30 days prior to being registered
             for protocol therapy

          -  No prior systemic chemotherapy for transitional cell carcinoma of the bladder (prior
             intravesical therapy is allowed); any other prior chemotherapy must have been
             completed > 5 years prior to initiation of therapy

          -  Prior radiation therapy is allowed provided that no radiation therapy was administered
             to the urinary bladder

               -  NOTE: No radiation therapy within 28 days prior to being registered for protocol
                  therapy; laboratory values must be obtained within 14 days prior to being
                  registered for protocol therapy

          -  Total bilirubin < 2.0 X upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) =< 2.5 X ULN

          -  Alanine aminotransferase (ALT) =< 2.5 X ULN

          -  Serum Creatinine < 2.5 X ULN

          -  Absolute neutrophil count (ANC) > 1.5 X K/mm^3

          -  Platelets > 100 K/mm^3

          -  International normalized ratio (INR) =< 1.2

          -  There are currently no known concomitant medications that must be discontinued prior
             to administration of registration on study and for the duration of sEphB4-HSA

          -  No clinically significant infections as judged by the treating investigator

          -  No pleural or pericardial effusion of any grade

          -  No uncontrolled angina, congestive heart failure or myocardial infraction (MI) within
             6 months prior to registration on study

          -  No diagnosed arrhythmias

          -  No abnormalities on pre-entry electrocardiogram, obtained within 28 days prior to
             being registered on study

          -  No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

          -  No abnormalities no history of diagnosed acquired bleeding disorders within one year
             (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy

          -  No abnormalities no history of ongoing or recent (less than or equal to 3 months of
             registration on protocol therapy) significant gastrointestinal bleeding

          -  No ongoing anti-coagulation and/or anti-platelet therapies allowed

          -  Patients with diagnosed uncontrolled hypertension (> 150/90 mmHg) are to be excluded

          -  Patients with hypertension controlled with medications are allowed

          -  No evidence of gross hematuria

          -  No evidence of hydronephrosis

          -  No evidence of a history of a stroke or myocardial infarction within the last 6 months
             prior to study enrollment

          -  No evidence of a history of wound healing complications prior to study enrollment